BioCardia to Participate in Upcoming Investor Conferences
BioCardia to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company’s management team will participate in the following upcoming investor conferences:
圣卡洛斯，加利福尼亚州，2021年8月13日(环球通讯社)-BioCardia®，Inc.纳斯达克：BCDA)，一家治疗心血管和肺部疾病的细胞和细胞衍生疗法的开发商，今天宣布，该公司的管理团队将参加即将召开的以下投资者大会：
Q3 Investor Summit Virtual Conferencefrom August 17-18, 2021 https://investorsummitgroup.com/conferences/BioCardia Corporate Presentation scheduled for 08/17 at 2pm Eastern Time (11am Pacific time)1-1 meetings available with Company Representatives for those interested – please sign up through conference website.SNN Network Virtual Event Conferencefrom August 17-19, 2021 https://conference.snn.network/BioCardia Corporate Presentation scheduled for 08/19 at 3pm Eastern Time (12pm Pacific time)1-1 meetings available with Company Representatives for those interested – please sign up through conference website.
第三季度投资者峰会虚拟会议从2021年8月17日至18日，https://investorsummitgroup.com/conferences/BioCardia公司演示定于东部时间08/17下午2点(太平洋时间上午11点)举行，感兴趣的公司代表可参加1-1次会议-请通过会议网站报名。SNN网络虚拟活动大会从2021年8月17日至19日，https://conference.snn.network/BioCardia公司演示定于东部时间08/19下午3点(太平洋时间下午12点)举行，感兴趣的公司代表可参加1-1次会议-请通过会议网站报名。
About BioCardia®
关于BioCardia®
BioCardia, Inc., headquartered in San Carlos, California, is a developer of two biotherapeutic platforms – the CardiAMPTMautologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogenic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases. These platforms underly four product candidates, each with the potential to meaningfully benefit millions of patients. Three of these investigational therapies are enabled by the Company’s proprietary biotherapeutic delivery platforms, which the Company also selectively licenses to other biotherapeutic development firms.
总部设在加利福尼亚州圣卡洛斯的BioCardia公司是两种生物治疗平台的开发商，一种是用于心血管适应症的心脏AMPT-Mautologous骨髓来源单核细胞疗法，另一种是用于心血管和肺部疾病的NK1R+同种异体骨髓来源间充质干细胞疗法。这些平台低于四种候选产品，每种产品都有可能让数百万患者受益。其中三种研究疗法是由该公司专有的生物治疗输送平台提供的，该公司还选择性地将该平台授权给其他生物治疗开发公司。
INVESTOR CONTACT:
投资者联系方式：
David McClung, Chief Financial Officer
首席财务官David McClung
investors@BioCardia.com
邮箱：Investors@BioHeara.com
(650) 226-0120
(650) 226-0120
MEDIA CONTACT:
媒体联系人：
Anne Laluc, Marketing
安妮·拉鲁克(Anne Laluc)，市场营销
Email: alaluc@biocardia.com
电子邮件：alaluc@biardia.com
Phone: 650-226-0120
电话：650-226-0120